Proton pump inhibitor kidney damage litigation MDL 2789: the $590 million in settlements, the 11,300 cases still pending, the AstraZeneca $425 million resolution, and the Takeda and P&G claims still in play

Proton pump inhibitors are among the most widely used medications in the world. Nexium, Prilosec, Prevacid, Protonix, Dexilant: these acid-reducing drugs have been taken by tens of millions of Americans for heartburn, gastroesophageal reflux disease (GERD), and stomach ulcers. Many were available over the counter, taken daily for years or decades without medical supervision.

The litigation alleges that long-term PPI use causes serious kidney damage, and that the manufacturers knew about the risk and failed to warn consumers. The MDL (In Re: Proton Pump Inhibitor Products Liability Litigation, MDL 2789) in the U.S. District Court for the District of New Jersey before Judge Claire C. Cecchi has been one of the largest pharmaceutical mass torts by case volume: 18,706 cases filed in total, with 11,322 still active as of early 2026.

The litigation has already produced substantial settlements. AstraZeneca (Nexium, Prilosec) settled approximately 11,000 cases for $425 million in October 2023. Combined with settlements from other manufacturers, the aggregate payout has reached approximately $590 million. But the litigation is not over: Takeda (Prevacid) and Procter & Gamble have not reached global settlements, thousands of cases remain pending, and initial settlement distributions only began reaching claimants in late 2025.

The drugs and the mechanism

Proton pump inhibitors work by blocking the hydrogen-potassium ATPase enzyme system in the stomach's parietal cells, reducing gastric acid production. They are the most potent class of acid-suppressing drugs available and were designed for short-term use (4 to 8 weeks for healing of gastric and duodenal ulcers, 8 to 12 weeks for erosive esophagitis).

In practice, many patients took PPIs continuously for years or decades, often without periodic reassessment of whether the medication was still needed. The widespread availability of over-the-counter formulations (Prilosec OTC, Nexium 24HR, Prevacid 24HR) contributed to long-term unsupervised use.

The alleged kidney injuries include chronic kidney disease (CKD), a progressive loss of kidney function that can ultimately require dialysis or kidney transplant; acute interstitial nephritis (AIN), inflammation of the kidney tissue that can cause sudden kidney damage; acute kidney injury (AKI), a rapid decline in kidney function; and end-stage renal disease (ESRD), complete or near-complete kidney failure requiring dialysis.

A 2016 study published in JAMA Internal Medicine found that PPI users had a 20-50% increased risk of chronic kidney disease compared to non-users. The risk increased with longer duration of use, higher doses, and the absence of a clear medical indication for the medication. Subsequent studies confirmed and refined these findings, establishing the epidemiological basis for the litigation.

The plaintiffs allege that manufacturers, particularly AstraZeneca (which dominated the PPI market with Nexium and Prilosec), knew about the kidney risks as early as 2004 but did not adequately warn consumers or healthcare providers for a decade.

The $425 million AstraZeneca settlement

In October 2023, AstraZeneca announced a $425 million settlement to resolve approximately 11,000 Nexium and Prilosec kidney damage cases in the MDL. The settlement was announced days before the first bellwether trial (James Reider v. AstraZeneca Pharmaceuticals LP, et al.) was scheduled to begin on October 10, 2023.

The settlement resolved the largest block of cases in the MDL, as AstraZeneca was the manufacturer of both Nexium (esomeprazole) and Prilosec (omeprazole), the two most widely used PPIs.

Settlement payouts have ranged from $20,000 to over $150,000 per case, depending on the severity of the kidney injury, the duration of PPI use, the strength of the causation evidence, and other case-specific factors. Initial distributions began in late 2025, with 653 cases fully resolved and paid as of March 2026 (approximately 5% of the active caseload).

The slow pace of distribution is common in large pharmaceutical mass torts: administrative processing, claims verification, and the volume of cases all contribute to extended timelines. Earlier filers have generally received payouts sooner.

The remaining defendants

The AstraZeneca settlement resolved the largest block, but the litigation continues against other manufacturers:

Takeda Pharmaceuticals (Prevacid / lansoprazole) has not reached a global settlement. A bellwether trial (Conaway v. Takeda) was scheduled but postponed, and a stay on all deadlines in the MDL remains in effect as of 2026.

Procter & Gamble (Prilosec OTC and other over-the-counter formulations) has not reached a global settlement.

Pfizer/Wyeth (Protonix / pantoprazole) resolved some cases as part of the aggregate settlements.

GlaxoSmithKline and other smaller manufacturers contributed to the aggregate settlements.

The combined settlements across all defendants total approximately $590 million. The remaining claims against Takeda and P&G represent a substantial tail of the litigation.

The FDA warning timeline

The FDA's response to the kidney risk accumulated gradually, following the same pattern seen in the fluoroquinolone antibiotic litigation: scientific evidence emerged, warnings accumulated, and the allegations center on the gap between when the manufacturers knew and when consumers were told.

2010: The FDA issued an initial safety warning about the risk of hypomagnesemia (dangerously low magnesium levels) with long-term PPI use, which can contribute to kidney injury.

2014: Studies began linking PPI use to acute interstitial nephritis, a specific form of kidney inflammation.

2016: The landmark JAMA Internal Medicine study established the 20-50% increased CKD risk for long-term PPI users, providing the epidemiological foundation for the litigation.

2016-2017: The FDA issued safety communications about the risks of long-term PPI use, including bone fractures, Clostridium difficile infection, and kidney disease.

2022: A meta-analysis in the American Journal of Clinical Oncology found that PPI use increases the risk of certain cancers, including stomach cancer, adding another category of potential injury.

The plaintiffs allege that AstraZeneca was aware of kidney risk data as early as 2004 (through its own clinical trials and post-marketing surveillance) but did not adequately update the drug labels for approximately a decade. The label delay is the central failure-to-warn allegation.

The types of kidney injury

The kidney injuries in the PPI litigation fall along a spectrum of severity, which directly affects case valuation:

Acute interstitial nephritis (AIN) is inflammation of the kidney tissue caused by a drug reaction. AIN can be reversible if the PPI is stopped promptly, or it can progress to chronic damage if the use continues. AIN is the earliest-stage injury and is often the triggering event that leads to a CKD diagnosis.

Chronic kidney disease (CKD) is a progressive, irreversible decline in kidney function measured by the glomerular filtration rate (GFR). CKD is staged from Stage 1 (mild) to Stage 5 (kidney failure). Most PPI kidney cases involve CKD Stage 3 or higher, where the functional impairment is clinically significant.

Acute kidney injury (AKI) is a sudden decline in kidney function that can occur at any CKD stage. AKI episodes can accelerate the progression to end-stage disease.

End-stage renal disease (ESRD) is complete or near-complete kidney failure requiring dialysis (hemodialysis or peritoneal dialysis) or kidney transplant. ESRD cases have the highest damages in the litigation because dialysis is a life-altering, ongoing medical intervention.

The settlement values track the severity: AIN cases with full recovery value less than progressive CKD cases, which value less than ESRD cases requiring dialysis. The $20,000-$150,000+ range in the AstraZeneca settlement reflects this severity spectrum.

The eligibility criteria for claims

The PPI kidney litigation applies to individuals who:

Used a proton pump inhibitor (Nexium, Prilosec, Prevacid, Protonix, Dexilant, or generic equivalents) for an extended period (typically more than one year, though shorter-duration claims exist for AIN).

Were subsequently diagnosed with a kidney injury (CKD, AIN, AKI, or ESRD) confirmed by medical records (lab results showing elevated creatinine, reduced GFR, kidney biopsy, or dialysis records).

Can establish a temporal relationship between the PPI use and the kidney injury onset (the kidney diagnosis postdates the PPI use, and there is no alternative explanation for the kidney disease).

Alternative explanations that the defendants raise include diabetes, hypertension, and other conditions that independently cause kidney disease. The strongest PPI cases involve patients without these confounding conditions, where the PPI use is the most plausible cause of the kidney injury.

How PPI cases compare to other mass torts

The PPI litigation shares features with several Halstonberg-covered mass torts:

Fluoroquinolone antibiotic litigation similarly involves a widely prescribed medication class, a progressive accumulation of FDA warnings, and an allegation that manufacturers knew about risks for years before adequately warning consumers.

Zantac/ranitidine NDMA contamination involves another gastrointestinal medication with alleged carcinogenic contamination, though the injury mechanism differs (chemical contamination vs. pharmacological effect).

Depo-Provera meningioma (MDL 3140) shares the pattern of a long-used medication with a delayed recognition of a serious injury, and a failure-to-warn theory based on when the manufacturer knew about the risk.

The PPI litigation is distinctive in its size (18,706 cases filed), the substantial settlement amounts already paid ($590 million aggregate), and the ongoing nature of the claims against non-settling defendants.

Practical guidance

For someone who used a PPI long-term and developed kidney disease:

The litigation is still accepting cases, though the AstraZeneca settlement has resolved the largest block. Claims against Takeda (Prevacid) and P&G (OTC formulations) remain active.

The key evidence: medical records documenting the kidney diagnosis (CKD, AIN, AKI, or ESRD), pharmacy records establishing long-term PPI use (duration and which specific PPI product), and the temporal relationship between the PPI use and the kidney injury onset.

Earlier filing is advantageous. Settlement distributions have been slow (5% of active cases paid as of March 2026), and earlier filers have generally been processed sooner. There is also a risk that settlement funds could become limited as more claims are processed.

If you used Nexium or Prilosec specifically, the AstraZeneca settlement is the applicable framework. If you used Prevacid (Takeda) or an over-the-counter PPI from P&G, the claims against those manufacturers are still pending and may produce separate settlements.

The statute of limitations varies by state and depends on when the plaintiff knew or should have known of the connection between the PPI use and the kidney injury. The "discovery rule" is critical: for many patients, the connection was not apparent until years after the kidney disease was diagnosed.

Consult with a mass tort attorney who is actively working in MDL 2789. The settlement infrastructure is established for AstraZeneca cases, and the claims process has specific requirements and deadlines.

The PPI litigation is one of the largest pharmaceutical mass torts by both case volume and aggregate settlement value. For patients with documented long-term PPI use and subsequent kidney disease, the settlement framework provides a structured path to compensation, though the pace of distribution means patience and prompt filing are both important.